Paclitaxel Poliglumex
drug drugOn this page
Also known as CT-2103L-polyglutamic paclitaxelOpaxioPG-TXLXyotax
Summary
Paclitaxel Poliglumex (CHEMBL2108628) is a phase-3 clinical-stage small molecule (ATC L01CD03); indicated across 13 conditions including neoplasm and non-small cell lung carcinoma.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Small molecule
- ATC class: L01CD03
- Indications: 13 conditions
- Clinical trials: 20
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2108628 |
| Name | Paclitaxel Poliglumex |
| Type | Small molecule |
| Max phase | 3 |
| ATC | L01CD03 |
Also known as: CT-2103, L-polyglutamic paclitaxel, Opaxio, Paclitaxel poliglumex, PG-TXL, Xyotax, PACLITAXEL POLIGLUMEX
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
12 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.
| Disease (in trials) | Phase | MONDO | EFO |
|---|---|---|---|
| neoplasm | 3 | MONDO:0005070 | EFO:0000616 |
| non-small cell lung carcinoma | 3 | MONDO:0005233 | EFO:0003060 |
| undifferentiated carcinoma | 3 | MONDO:0005617 | EFO:0006772 |
| lung neoplasm | 3 | MONDO:0021117 | MONDO:0008903 |
| prostate adenocarcinoma | 2 | MONDO:0005082 | EFO:0000673 |
| brain neoplasm | 2 | MONDO:0021211 | EFO:0003833 |
| breast neoplasm | 2 | MONDO:0021100 | MONDO:0007254 |
| squamous cell carcinoma | 1 | MONDO:0005096 | EFO:0000707 |
| peritoneal neoplasm | 1 | MONDO:0006901 | MONDO:0002087 |
| fallopian tube neoplasm | 1 | MONDO:0021092 | MONDO:0002158 |
| ovarian cancer | 1 | MONDO:0008170 | MONDO:0008170 |
| colorectal neoplasm | 1 | MONDO:0005335 | MONDO:0005575 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 20.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 8 |
| PHASE3 | 7 |
| PHASE1 | 3 |
| PHASE1/PHASE2 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00054184 | PHASE3 | TERMINATED | Polyglutamate Paclitaxel Compared With Docetaxel in Treating Patients With Progressive Non-Small Cell Lung Cancer |
| NCT00054197 | PHASE3 | TERMINATED | Polyglutamate Paclitaxel Compared With Gemcitabine or Vinorelbine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer |
| NCT00054210 | PHASE3 | TERMINATED | Polyglutamate Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer |
| NCT00108745 | PHASE3 | UNKNOWN | Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer |
| NCT00269828 | PHASE3 | TERMINATED | A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy. |
| NCT00551733 | PHASE3 | TERMINATED | Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer |
| NCT00576225 | PHASE3 | WITHDRAWN | CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL |
| NCT00017017 | PHASE1/PHASE2 | COMPLETED | CT-2103 in Treating Patients With Recurrent Ovarian Epithelial or Fallopian Tube Cancer or Primary Peritoneal Cancer |
| NCT00045682 | PHASE2 | COMPLETED | CT-2103 in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer |
| NCT00069901 | PHASE2 | COMPLETED | Phase II CT-2103/Carboplatin in Ovarian Cancer |
| NCT00148707 | PHASE2 | COMPLETED | Study of Xyotax (CT-2103) in Patients With Metastatic Breast Cancer |
| NCT00265733 | PHASE2 | COMPLETED | Paclitaxel Poliglumex and Capecitabine in Treating Patients With Metastatic Breast Cancer |
| NCT00352690 | PHASE2 | TERMINATED | A Phase II Study of Radiation Therapy, Paclitaxel Poliglumex, and Carboplatin in Stage III Non-Small Cell Lung Cancer |
| NCT00459810 | PHASE2 | TERMINATED | Paclitaxel Poliglumex and Estradiol in Treating Patients With Stage IV Prostate Cancer |
| NCT00487669 | PHASE2 | COMPLETED | Phase II Study of Combination of Paclitaxel Poliglumex and Alimta for Advanced Non-small Cell Lung Cancer (NSCLC) |
| NCT00660218 | PHASE1/PHASE2 | COMPLETED | A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer |
| NCT01227408 | PHASE2 | WITHDRAWN | Neoadjuvant Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer |
| NCT00060359 | PHASE1 | COMPLETED | Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer |
| NCT00270907 | PHASE1 | COMPLETED | CT-2103 in Combination With Gemcitabine in Metastatic Breast Cancer |
| NCT00598247 | PHASE1 | COMPLETED | A Pilot Study of PPX in Women With Metastatic Colorectal Cancer |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- In clinical trials for: neoplasm, non-small cell lung carcinoma, lung neoplasm, prostate adenocarcinoma, brain neoplasm, breast neoplasm